SURF News and Press, Surface Oncology Inc. From 06/29/22

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company’s boar...

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the ...

- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies ...

– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC – – Data support continued evaluation of SRF388 in NSCLC, RCC, and first line HCC – – Surface pla...

Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either. Despite having partnerships with big names, the stock does not move up. For further details see: Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Sto...

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will particip...

The shares of Surface Oncology (NASDAQ:SURF) traded higher in the premarket Monday after the cancer-focused biotech announced its upcoming milestones and highlighted the solid cash position with its 1Q 2022 financials. The company beat Street forecasts for both revenue and net income after re...

Surface Oncology press release (NASDAQ:SURF): Q1 GAAP EPS of $0.13 beats by $0.38. Revenue of $30M (+1740.5% Y/Y) beats by $17.42M. “The first quarter of 2022 marked the beginning of a data-rich year for Surface, starting with the presentation of preclinical and translational SRF388 da...

– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $ 21 million raised in the quarter through ATM facility – – ...

CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to five ...